Stonegate Capital Partners Updates Coverage On GoHealth Inc. (GOCO) 2025 Q2

Rhea-AI Summary

GoHealth Inc. (NASDAQ: GOCO) reported challenging Q2 2025 results, with net revenues declining 11.2% year-over-year to $94.0M. The company experienced significant decreases in partner revenue (-44.4%) and non-agency revenue (-79.4%), partially offset by growth in GoHealth Protect segment.

The company secured $115M in new and rolled-up loans and amended its credit agreement to waive near-term principal payments. Q2 resulted in a $115.9M net loss, including a $53M intangible asset impairment charge, though adjusted EBITDA showed slight improvement to -$11.3M year-over-year. Cost efficiency improved with marketing and consumer care expenses declining 26% and 33% respectively.

Positive

• None.

Negative

• Net revenues declined 11.2% year-over-year to $94.0M
• Partner revenue dropped 44.4% and non-agency revenue fell 79.4%
• Reported substantial net loss of $115.9M in Q2
• $53M intangible asset impairment charge
• Total submissions declined 7.5%

Dallas, Texas--(Newsfile Corp. - August 8, 2025) - GoHealth Inc. (NASDAQ: GOCO): Stonegate Capital Partners updates their coverage on GoHealth Inc. (NASDAQ: GOCO). GoHealth, Inc. delivered a challenged second quarter in 2025, highlighted by revenue declines and contracting margins. Net revenues decreased 11.2% year-over-year to $94.0M, driven by a decrease of 44.4% and 79.4% in partner revenue and non-agency revenue, respectively. This decrease was buoyed by a strong increase in other revenues, spearheaded by GoHealth Protect, discussed below. This overall decline was driven in large part by the telegraphed softness in the overall market. Management notes that they will continue to read and react to the market, taking advantage of opportunities where they see fit. As the Company continues through 2025, and following the updated strategic initiatives mentioned below, management remains focused on the upcoming AEP.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• Secured $115M in new and rolled-up loans, amended credit agreement waiving near-term principal payments, and created $250M debt basket to pursue strategic deals.
• Reported a $115.9M net loss in Q2, impacted by a $53M intangible asset impairment charge; adjusted EBITDA improved slightly y/y to -$11.3M.
• Marketing and consumer care expenses fell 26% and 33% y/y, respectively, driving improved cost efficiency per submission despite a 7.5% decline in total submissions.

Click image above to view full announcement.

---

About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.

Contacts:

Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/261805

FAQ

What were GoHealth's (GOCO) Q2 2025 financial results?

GoHealth reported net revenues of $94.0M, down 11.2% year-over-year, with a net loss of $115.9M including a $53M impairment charge. Adjusted EBITDA was -$11.3M.

How much did GOCO's partner and non-agency revenues decline in Q2 2025?

Partner revenue decreased by 44.4% while non-agency revenue declined by 79.4% year-over-year.

What cost reduction measures did GoHealth (GOCO) implement in Q2 2025?

GoHealth reduced marketing expenses by 26% and consumer care expenses by 33% year-over-year, improving cost efficiency per submission.

What new financing did GoHealth (GOCO) secure in Q2 2025?

GoHealth secured $115M in new and rolled-up loans, amended its credit agreement to waive near-term principal payments, and created a $250M debt basket for strategic deals.

How did GOCO's submission volumes perform in Q2 2025?

Total submissions declined by 7.5% year-over-year, though the company achieved improved cost efficiency per submission through expense reductions.